Literature DB >> 11936731

Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: vitamin A supplements do not prevent lesions.

Jorma Kokkonen1, Merja Möttönen, Tuomo J Karttunen, Marjatta Lanning.   

Abstract

Intensive chemotherapy (ICT) for a malignant disease in children may be associated with clinically significant mucosal lesions of the upper gastrointestinal tract. This prospective and randomized study was conducted to evaluate more thoroughly the mucosal damage and to find out whether vitamin A therapy might prevent the development of these lesions. Gastroduodenoscopy and non-invasive methods were used to examine a consecutive series of 20 patients (10 females, 10 males, aged 1-15 years) 4 weeks after initiating the therapy regimen. Half of the patients were randomized to take vitamin A supplements for 6 weeks. During a follow-up of 6 weeks, 13 (65%) reported some symptoms of the gastrointestinal (GI) tract, diarrhea and mouth pain being most prominent. Endoscopic abnormalities were found in 13 (65 %) subjects: esophagitis in 10, erosive duodenitis in 8, and gastritis in 7. Histologically, 11 subjects had duodenitis, 5 had gastritis, 3 had eosinophilic esophagitis, and 2 had lymphocytic esophagitis. Both endoscopic and histological abnormalities of the duodenum showed a close relationship with long-term (more than 2 weeks) granulocytopenia. The 4 patients with the most extensive endoscopic abnormalities were treated with HCl inhibitors, and re-endoscopy performed 4-8 weeks later showed complete recovery. The sugar permeability values, measured as the lactulose/mannitol ratio were comparable to the values obtained in the controls, and lactose intolerance was found in only 3 (20%) of the 15 children able to perform the breath test. Both the incidence of the reported GI symptoms and the endoscopically or histologically observed GI lesions were similar in the subjects randomized to take vitamin A supplements as in the controls. In this study, two-thirds of children with ICT showed erosive mucosal lesions of the upper gastrointestinal tract, and vitamin A therapy failed to prevent them. Endoscopic examination is recommended if a patient has severe symptoms indicative of mucosal pathology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936731     DOI: 10.1080/088800102753541332

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  5 in total

1.  Healing action of topical chamomile on 5-fluoracil induced oral mucositis in hamster.

Authors:  Vanessa C S Pavesi; Talita C C Lopez; Marco A T Martins; Manoel Sant'Ana Filho; Sandra K Bussadori; Kristianne P S Fernandes; Raquel A Mesquita-Ferrari; Manoela D Martins
Journal:  Support Care Cancer       Date:  2010-04-28       Impact factor: 3.603

Review 2.  The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis.

Authors:  Cesar A Migliorati; Loree Oberle-Edwards; Mark Schubert
Journal:  Support Care Cancer       Date:  2006-03-30       Impact factor: 3.603

Review 3.  Effects of vitamin a supplementation on immune responses and correlation with clinical outcomes.

Authors:  Eduardo Villamor; Wafaie W Fawzi
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

Review 4.  Systematic review of natural agents for the management of oral mucositis in cancer patients.

Authors:  Noam Yarom; Anura Ariyawardana; Allan Hovan; Andrei Barasch; Virginia Jarvis; Siri Beier Jensen; Yehuda Zadik; Sharon Elad; Joanne Bowen; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-06-14       Impact factor: 3.603

5.  A systematic review of integrative clinical trials for supportive care in pediatric oncology: a report from the International Society of Pediatric Oncology, T&CM collaborative.

Authors:  Andrea L Radossi; Katherine Taromina; Stacey Marjerrison; Caroline J Diorio; Raquel Similio; Festus Njuguna; Glenn M Afungchwi; Elena J Ladas
Journal:  Support Care Cancer       Date:  2017-10-13       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.